Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Non-Current Liabilities (2017 - 2025)

KalVista Pharmaceuticals' Total Non-Current Liabilities history spans 11 years, with the latest figure at $110.2 million for Q2 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 1732.29% to $110.2 million in Q2 2025 year-over-year; TTM through Apr 2025 was $110.2 million, a 1732.29% increase, with the full-year FY2025 number at $110.2 million, up 1732.29% from a year prior.
  • Total Non-Current Liabilities hit $110.2 million in Q2 2025 for KalVista Pharmaceuticals, up from $30.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for KALV hit a ceiling of $110.2 million in Q2 2025 and a floor of $1.1 million in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $17.2 million across 4 years, with a median of $6.3 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 67.22% in 2021 and later skyrocketed 1732.29% in 2025.
  • Tracing KALV's Total Non-Current Liabilities over 4 years: stood at $5.0 million in 2021, then increased by 29.73% to $6.5 million in 2023, then skyrocketed by 366.71% to $30.6 million in 2024, then skyrocketed by 260.75% to $110.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for KALV at $110.2 million in Q2 2025, $30.6 million in Q4 2024, and $4.7 million in Q4 2024.